Kenai Therapeutics
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic iPSC-derived dopamine neuron replacement cell therapies and gene-modified medicines for Parkinson's disease and related neurological conditions.
- Company typePrivate
- Founded2022
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kenai Therapeutics does
Kenai Therapeutics is a clinical-stage biotechnology company founded in 2022 and headquartered in San Diego, California, that develops off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies for neurological conditions, with an initial focus on idiopathic and genetically driven Parkinson's disease. The company was previously known as Ryne Bio and rebranded in conjunction with its 2024 Series A financing. Kenai serves patients with progressive neurodegenerative disease for whom existing therapies provide only symptomatic relief and no disease-modifying intervention.
The company's pipeline is built on a proprietary induced pluripotent stem cell (iPSC) platform derived from Nobel Prize-winning technology, which enables scalable, cryopreserved, donor-derived cell production. Lead asset RNDP-001 is an allogeneic iPSC-derived dopamine progenitor cell therapy designed to replace lost dopamine-producing neurons, repair neural circuitry, and restore motor function; it has received FDA Fast Track designation and entered a multi-center Phase 1 REPLACE trial, with the first patient dosed in December 2025 and initial safety and brain imaging data from up to 12 patients expected in 2026. Two preclinical gene-modified candidates, RNDP-002 (mild-to-severe Parkinson's) and RNDP-003 (early-onset genetically driven Parkinson's), expand the platform. Manufacturing is conducted under an exclusive partnership with FUJIFILM Cellular Dynamics, Inc.
Kenai is currently pre-revenue and intends to commercialize its cryopreserved, off-the-shelf cell therapy through an enterprise field sales model targeting hospital systems, academic medical centers, and neurology specialty clinics. The company has raised approximately $82M in Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures, and The Column Group, supplemented by California Institute for Regenerative Medicine grants across multiple tranches totaling roughly $16M. Revenue is expected to be generated only upon regulatory approval through product sales to institutional buyers, with the off-the-shelf format designed to integrate with standard hospital logistics and administration.
Kenai Therapeutics firmographics
Firmographics- Name
- Kenai Therapeutics
- Legal name
- Kenai Therapeutics Inc.
- Website
- https://kenaitx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic iPSC-derived dopamine neuron replacement cell therapies and gene-modified medicines for Parkinson's disease and related neurological conditions.
- Ownership category
- akta.pro rank
Kenai Therapeutics industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
- akta.pro secondary industries
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where Kenai Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kenai Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Cell Therapy Product Revenue: Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies for neurological conditions. Upon regulatory approval, the company plans to commercialize its pipeline of neuron replacement cell therapies, with RNDP-001 being the lead candidate for Parkinson's disease. Revenue will be generated through product sales to hospital systems, academic medical centers, and specialty neurology clinics upon commercialization. The company is currently pre-revenue as all programs are in clinical or preclinical development stages.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Kenai Therapeutics product offering
Product offeringCore offering
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions, primarily Parkinson's disease. Its lead candidate RNDP-001 is an iPSC-derived, cryopreserved dopamine progenitor cell therapy currently in Phase 1 clinical trials (REPLACE), with FDA Fast Track designation. The pipeline also includes gene-modified candidates RNDP-002 (mild-to-severe Parkinson's) and RNDP-003 (genetically driven, early-onset Parkinson's), manufactured under an exclusive partnership with FUJIFILM Cellular Dynamics.
Product overview
Kenai Therapeutics is a clinical-stage biotechnology company developing a pipeline of off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies for neurological conditions. The company's lead product RNDP-001 is an iPSC-derived dopamine progenitor cell therapy in Phase 1 clinical trials for Parkinson's disease. The pipeline includes RNDP-002 (gene-modified cell therapy for mild-severe Parkinson's) and RNDP-003 (gene-modified therapy for early onset Parkinson's). All products are built on the company's proprietary Nobel Prize-winning iPSC platform, with exclusive manufacturing partnership with FUJIFILM Cellular Dynamics.
Differentiator
Problem solved
Functional benefit
Products and services
- RNDP-001 iPSC-derived, allogeneic, cryopreserved dopamine progenitor cell therapy designed to replace lost dopamine-producing neurons, repair injured neural circuitry, and restore motor function in patients with moderate to moderate-severe idiopathic and inherited Parkinson's disease. Lead candidate currently in Phase 1 clinical trials (REPLACE) and granted FDA Fast Track designation; intended for administration via precision neurosurgical procedure at hospital sites.
- RNDP-002 Gene-modified iPSC-based cell therapy designed to resurrect injured cells and provide new functionality to reverse the course of disease in people with mild to severe forms of Parkinson's disease. Currently in preclinical development.
- RNDP-003
Quantifiable outcome
- Phase 1 REPLACE trial enrolled up to 12 patients with moderate to moderate-severe idiopathic Parkinson's disease, with initial safety, tolerability, and brain imaging data expected in 2026.
- +2 more outcomes
Companies that use Kenai Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Kenai Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Kenai Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Lilly Gateway Labs / Alexandria Real Estate EquitiescoreKenai established its research and laboratory facilities at Lilly Gateway Labs, operated in partnership with Alexandria Real Estate Equities, Inc., at the One Alexandria Square Megacampus in San Diego. The facility provides state-of-the-art wet lab space, a robust network of scientific and operational resources, and tailored programs for emerging biotech companies. Kenai retains strategic independence and ownership of its assets and intellectual property.
- FUJIFILM Cellular Dynamics, Inc.coreExclusive manufacturing partnership with FUJIFILM Cellular Dynamics, a leading developer and manufacturer of human iPSCs and iPSC-derived cells, to enable scalable, cryopreserved production of high-potency dopamine progenitor cells for clinical use. FUJIFILM Cellular Dynamics provides contract development and manufacturing (CDMO) services for Kenai's cell therapy pipeline.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Kenai Therapeutics competitors and assessment
Company assessmentDirect peers
- BlueRock Therapeutics: Bayer-owned clinical-stage biotech developing iPSC-derived engineered cell therapies, with lead programs in Parkinson's disease (dopaminergic neuron cell therapy) and cardiology. Most direct competitor to Kenai, with deeper resources and earlier clinical data.
- Aspen Neuroscience: Clinical-stage biotech developing autologous iPSC-derived dopamine neuron replacement therapies for Parkinson's disease. Direct competitor with similar modality (iPSC-derived dopamine cells), though using autologous rather than allogeneic platform.
- Sumitomo Pharma: Japanese pharmaceutical company partnering with Kyoto University's Yoshiki Sasai lab to develop iPSC-derived dopaminergic progenitor cells for Parkinson's disease. Pursues similar neuron replacement strategy with longer R&D track record.
- Century Therapeutics: Clinical-stage biotech developing allogeneic iPSC-derived immune cell therapies for cancer. Uses similar iPSC engineering platform with comparable manufacturing considerations and cryopreserved off-the-shelf product format.
Emerging players
- Sana Biotechnology: Clinical-stage biotech with cell engineering platform using both iPSC and viral gene therapy approaches. Pursues multiple cell therapy programs with focus on hypoimmune technology that could apply to Parkinson's-type indications.
- TreeFrog Therapeutics: French biotech developing iPSC-derived cell therapies using proprietary C-Stem technology platform. Pursues Parkinson's disease and other neurological indications with focus on scalable cell manufacturing.
Broad incumbents
- Bayer: Global pharmaceutical company that owns BlueRock Therapeutics. Broader regenerative medicine strategy through BlueRock covers Parkinson's cell therapy, providing financial and commercial scale advantages over independent players like Kenai.
- Vertex Pharmaceuticals: Large biotech with growing cell therapy franchise through Semma Therapeutics acquisition (Type 1 diabetes) and other programs. Derek Hei's previous tenure at Vertex signals connection to broader cell therapy ecosystem.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Kenai Therapeutics social profiles
Digital presenceKenai Therapeutics compliance and trust
Trust signalCompliance1 record
Kenai Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kenai Therapeutics leadership team
Management profileNumber of profiles
Profiles15 records
Kenai Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kenai Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kenai Therapeutics
What does Kenai Therapeutics do?
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions, primarily Parkinson's disease. Its lead candidate RNDP-001 is an iPSC-derived, cryopreserved dopamine progenitor cell therapy currently in Phase 1 clinical trials (REPLACE), with FDA Fast Track designation. The pipeline also includes gene-modified candidates RNDP-002 (mild-to-severe Parkinson's) and RNDP-003 (genetically driven, early-onset Parkinson's), manufactured under an exclusive partnership with FUJIFILM Cellular Dynamics.
Is Kenai Therapeutics a public or private company?
Kenai Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kenai Therapeutics founded?
Kenai Therapeutics was founded in 2022. It employs 11 to 50 people.
Where is Kenai Therapeutics based?
Kenai Therapeutics is headquartered in San Diego, United States, in the North America region.
How does Kenai Therapeutics make money?
One revenue line is on record: cell Therapy Product Revenue.
Who are Kenai Therapeutics's main competitors?
Direct peers on record are BlueRock Therapeutics, Aspen Neuroscience, Sumitomo Pharma and Century Therapeutics. Emerging players are Sana Biotechnology and TreeFrog Therapeutics. Broad incumbents are Bayer and Vertex Pharmaceuticals.
Does Kenai Therapeutics have an API?
No public API is recorded for Kenai Therapeutics.
What industry is Kenai Therapeutics in?
Kenai Therapeutics's product category is Cell Therapy. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 8731.